RNAC - Cartesian Therapeutics Inc
IEX Last Trade
13.905
-1.005 -7.228%
Share volume: 63,678
Last Updated: Fri 30 Aug 2024 09:53:41 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$14.91
-1.01
-6.74%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-08 | 2022-11-03 | 2023-03-02 | 2023-05-04 | 2023-08-17 | 2023-11-13 | 2024-03-07 | 2024-05-08 | |
Assets | |||||||||
Total Assets | 188.068 M | 178.265 M | 165.886 M | 155.693 M | 139.506 M | 106.034 M | 305.050 M | 325.207 M | |
Current Assets | 172.572 M | 159.677 M | 148.138 M | 138.392 M | 122.725 M | 89.869 M | 90.729 M | 111.109 M | |
Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Other Current Assets | 6.522 M | 6.310 M | 3.778 M | 3.785 M | 4.258 M | 3.493 M | 4.967 M | 3.315 M | |
Short Term Investments | 6.522 M | 6.310 M | 3.778 M | 3.785 M | 4.258 M | 3.493 M | 4.967 M | 3.315 M | |
Total Receivables | 23.994 M | 6.925 M | 9.758 M | 8.682 M | 6.440 M | 6.773 M | 8.851 M | 4.376 M | |
Current Cash | 142.056 M | 146.442 M | 134.602 M | 125.925 M | 112.027 M | 79.603 M | 76.911 M | 103.418 M | |
Total Non-current Assets | 15.496 M | 18.588 M | 17.748 M | 17.301 M | 16.781 M | 16.165 M | 214.321 M | 214.098 M | |
Property Plant Equipment | 2.833 M | 2.904 M | 2.794 M | 2.765 M | 2.593 M | 2.421 M | 2.113 M | 2.402 M | |
Other Assets | 9.284 M | 12.084 M | 11.643 M | 11.225 M | 10.811 M | 10.367 M | 10.068 M | 9.556 M | |
Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 150.600 M | 150.600 M | |
Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 48.163 M | 48.163 M | |
Liabilities and shareholders’ equity | |||||||||
Total Liabilities and shareholders’ equity | 188.068 M | 178.265 M | 165.886 M | 155.693 M | 139.506 M | 106.034 M | 305.050 M | 325.207 M | |
Total liabilities | 98.462 M | 93.358 M | 72.058 M | 81.114 M | 74.058 M | 45.705 M | 444.680 M | 442.007 M | |
Total current liabilities | 33.763 M | 23.728 M | 25.077 M | 26.531 M | 29.367 M | 19.939 M | 68.209 M | 36.654 M | |
Accounts Payable | 1.013 M | 214.000 K | 316.000 K | 1.063 M | 267.000 K | 375.000 K | 3.150 M | 2.517 M | |
Other liabilities | 34.047 M | 38.909 M | 19.140 M | 28.738 M | 21.741 M | 17.072 M | 351.829 M | 381.272 M | |
Current long term debt | 4.410 M | 7.431 M | 10.084 M | 11.889 M | 11.964 M | 1.787 M | 2.166 M | 2.229 M | |
Long term debt | 30.652 M | 30.721 M | 27.841 M | 25.845 M | 22.950 M | 8.694 M | 8.789 M | 8.228 M | |
Other liabilities | 34.047 M | 38.909 M | 19.140 M | 28.738 M | 21.741 M | 17.072 M | 351.829 M | 381.272 M | |
Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Total Shareholder equity | 89.606 M | 84.907 M | 93.828 M | 74.579 M | 65.448 M | 60.329 M | -139.630 M | -116.800 M | |
Common stock | 148.506 M | 152.850 M | 153.446 M | 153.346 M | 153.442 M | 154.805 M | 5.295 M | 180.467 K | |
Retained earnings | -392.937 M | -400.830 M | -394.937 M | -416.600 M | -427.987 M | -436.989 M | -614.647 M | -671.471 M |